PLAY PODCASTS
Key Insights from Attending ASH 2025

Key Insights from Attending ASH 2025

Treating Blood Cancers

January 13, 202633m 51s

Audio is streamed directly from the publisher (media.blubrry.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC

Recorded on December 18, 2025


Lore Gruenbaum, PhD
Lore Gruenbaum, PhD
Chief Scientific Officer & Senior Vice President of Research
Blood Cancer United
Washington, DC
Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!

Additional Blood Cancer United Resources: